Page 4 - Lexaria Bioscience News Today

Insiders were net buyers of Lexaria Bioscience Corp.'s ( NASDAQ:LEXX ) stock during the past year. That is, insiders...

Lexaria Announces Closing of $3.6 Million Registered Direct Offering ...

Lexaria Bioscience shares are trading lower by 6.5% Thursday morning. The company finalized agreements for a registered direct offering.

KELOWNA, BC / ACCESSWIRE / February 15, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced that it has entered into definitive agreements for the purchase and sale of 1,558,443 shares of common stock (or common stock equivalents in lieu thereof) at a purchase price of $2.31 per share (or per common stock equivalent in lieu thereof) in a registered direct offering priced at-th...

Lexaria Bioscience (NASDAQ:LEXX – Get Free Report) and Adial Pharmaceuticals (NASDAQ:ADIL – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, risk, valuation, profitability and institutional ownership. Analyst Recommendations This is a summary of […]

Lexaria Bioscience (NASDAQ: ) just reported results for the first quarter of 2024. InvestorPlace Earnings is a project that leverages data from TradeSmith to…

Lexaria Unveils Extensive Planned 2024 GLP-1 Study Program

(MENAFN - Investor Brand Network) Lexaria Bioscience, a global innovator in drug delivery platforms, has developed and patented the DehydraTECH(TM) drug delivery platform technology The company ... ...

Lexaria Bioscience Corp. reported earnings results for the first quarter ended November 30, 2023. For the first quarter, the company reported sales was USD 0.151278 million compared to USD 0.097735...